GSK Launches ReQuip XL(R) (ropinirole Prolonged-release Tablets) A New Once Daily Formulation For The Treatment Of Parkinson’s Disease
GlaxoSmithKline (GSK) have announced the launch of a new treatment for Parkinson’s disease (PD) in the UK. ReQuip XL® (ropinirole prolonged-release tablets) is the UK’s first and only once-daily non-ergot oral dopamine agonist available for the treatment of PD1, providing continuous delivery of ropinirole from a single daily dose2.
More: continued here
Filed under: Parkinson's Disease on May 22nd, 2008